2026-526756-31-00招募中1 期
A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 46
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaExtranodal Marginal Zone LymphomaLymphomaNCT07583810City of Hope Medical Center35
招募中
1 期
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)Acute Myeloid LeukemiaNCT07384715Genmab78
尚未招募
2 期
Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerHER2-addicted Breast CancerNCT07772245Polly A. Niravath, MD30
招募中
1 期
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIVNCT07392372BioNTech SE67
招募中
1 期
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.Endometrial CancerPlatinum-resistant Ovarian Cancer (PROC)Metastatic Ovarian CancerMetastatic Endometrial CancerOvarian CancerNCT07755436ArriVent BioPharma, Inc.180